Molecular Analysis for Personalised Therapy (MAP) is a leading congress in precision medicine in oncology in Europe, established by key opinion leaders in the field.

By attending MAP, participants will learn how to integrate insights from tumor sample analysis into daily practice, how to seek and identify actionable mutations in patient DNA and how to provide the best possible personalized treatment.

The MAP Congress has established itself as a meeting place for all specialists willing to create a bright future for precision medicine in oncology, by delivering a highly specific, minimally toxic and dramatically effective treatment for each patient.